Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Stefan FaderlHagop M Kantarjian

Abstract

To compare the receipt of clofarabine plus cytarabine (Clo+Ara-C arm) with cytarabine (Ara-C arm) in patients ≥ 55 years old with refractory or relapsed acute myelogenous leukemia (AML). Patients were randomly assigned to receive either clofarabine (Clo) 40 mg/m(2) or a placebo followed by Ara-C 1 g/m(2) for five consecutive days. The primary end point was overall survival (OS). Secondary end points included event-free survival (EFS), 4-month EFS, overall remission rate (ORR; complete remission [CR] plus CR with incomplete peripheral blood count recovery), disease-free survival (DFS), duration of remission (DOR), and safety. Among 320 patients with confirmed AML (median age, 67 years), the median OS was 6.6 months in the Clo+Ara-C arm and 6.3 months in the Ara-C arm (hazard ratio [HR], 1.00; 95% CI, 0.78 to 1.28; P = 1.00). The ORR was 46.9% in the Clo+Ara-C arm (35.2% CR) versus 22.9% in the Ara-C arm (17.8% CR; P < .01). EFS (HR: 0.63; 95% CI, 0.49 to 0.80; P < .01) and 4-month EFS (37.7% v 16.6%; P < .01) favored the Clo+Ara-C arm compared with Ara-C arm, respectively. DFS and DOR were similar in both arms. Overall 30-day mortality was 16% and 5% for CLO+Ara-C and Ara-C arms, respectively. In the Clo+Ara-C and Ara-C arms, th...Continue Reading

References

Jan 24, 1992·Journal of Medicinal Chemistry·J A MontgomeryJ A Secrist
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter L GreenbergJacob M Rowe
Feb 22, 2005·Cancer Chemotherapy and Pharmacology·Todd CooperVarsha Gandhi
Feb 4, 2006·Blood·Frederick R AppelbaumStephen H Petersdorf
Apr 16, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mehdi HamadaniEdward A Copelan
May 14, 2008·Reviews on Recent Clinical Trials·Jonathan Kell
Oct 7, 2009·British Journal of Haematology·Mark R LitzowUNKNOWN Eastern Cooperative Oncology Group Leukemia Committee
Jun 19, 2010·Blood·Jacob M Rowe, Martin S Tallman
Jul 11, 2012·Journal of the Egyptian National Cancer Institute·Basma M ElgamalHeba N Raslan

❮ Previous
Next ❯

Citations

May 15, 2013·Current Hematologic Malignancy Reports·Nicholas D Reese, Gary J Schiller
Dec 7, 2013·Best Practice & Research. Clinical Haematology·Farhad Ravandi
Dec 7, 2013·Best Practice & Research. Clinical Haematology·Jeffrey E Lancet
Aug 2, 2013·Future Oncology·Courtney D DiNardoFarhad Ravandi
Mar 20, 2014·Current Hematologic Malignancy Reports·Amir T Fathi, Yi-Bin Chen
Sep 11, 2012·Leukemia & Lymphoma·Hady GhanemElias Jabbour
Jul 28, 2013·Leukemia & Lymphoma·Aziz Nazha, Farhad Ravandi
Sep 14, 2012·Expert Opinion on Pharmacotherapy·Katarzyna Jamieson, Olatoyosi Odenike
May 22, 2013·Expert Opinion on Pharmacotherapy·Ciara FreemanFrancis Giles
Dec 15, 2015·Blood·Hervé Dombret, Claude Gardin
Sep 14, 2016·Hospital Pharmacy·Kristin V HoJ Aubrey Waddell
Jun 12, 2013·American Journal of Hematology·Clémentine SarkozyHervé Dombret
Apr 10, 2016·Journal of Pharmaceutical and Biomedical Analysis·Božena BüttnerHolger Knoth
Aug 4, 2015·The Lancet Oncology·Martin Bornhäuser
Apr 14, 2016·Journal of the American Medical Directors Association·Hirva MamdaniHeiko Konig
Apr 9, 2015·Blood·Felicitas TholArnold Ganser
Jan 13, 2015·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Bernard L MariniJerod L Nagel
Aug 3, 2014·Clinical Lymphoma, Myeloma & Leukemia·Kamal K S AbbiDavid F Claxton
Apr 10, 2013·Cancer Treatment Reviews·Pawel Robak, Tadeusz Robak
Feb 4, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Gary J Schiller
May 2, 2015·Journal of Clinical Medicine·Nestor R RamosChristopher S Hourigan
Dec 20, 2014·Leukemia Research·Raphael ItzyksonClaude Gardin
Dec 3, 2014·Critical Reviews in Oncology/hematology·Claudio Fozza
May 3, 2016·The Lancet. Haematology·Felicetto Ferrara
Jul 2, 2016·Blood Cancer Journal·I De Kouchkovsky, M Abdul-Hay
Jul 17, 2016·Cancer Chemotherapy and Pharmacology·Jeong-Hyun KimSung-Soo Yoon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.